CD274 and cancer: It took nearly ten years until the portfolio of effective drugs finally expanded to cancer immunotherapy, and recent studies such as the positive phase III study (IMbrave150) with the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-angiogenesis) open a new era in the treatment of this deadly disease [51,52].